TMEM-ing the Tide: Gene Therapy Holds Promise for ARVC5
- PMID: 40208928
- PMCID: PMC12151322
- DOI: 10.1161/CIRCRESAHA.125.326367
TMEM-ing the Tide: Gene Therapy Holds Promise for ARVC5
Keywords: Editorials; arrhythmias, cardiac; cardiomyopathies; genetic therapy; myocytes, cardiac.
Conflict of interest statement
F. Sheikh is a co-founder and shareholder of Papillon Therapeutics Inc and MyoTherapeutix Inc as well as a consultant and shareholder of LEXEO Therapeutics Inc. The other authors report no conflicts.
Comment on
-
Overexpression of Wild-Type TMEM43 Improves Cardiac Function in Arrhythmogenic Right Ventricular Cardiomyopathy Type 5.Circ Res. 2025 Apr 11;136(8):830-844. doi: 10.1161/CIRCRESAHA.124.325848. Epub 2025 Mar 17. Circ Res. 2025. PMID: 40091736 Free PMC article.
References
-
- van Lint FHM, Murray B, Tichnell C, Zwart R, Amat N, Lekanne Deprez RH, Dittmann S, Stallmeyer B, Calkins H, van der Smagt JJ, et al. Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. Circ Genom Precis Med. 2019;12:e002467. - PubMed
-
- Merner ND, Hodgkinson KA, Haywood AFM, Connors S, French VM, Drenckhahn J-D, Kupprion C, Ramadanova K, Thierfelder L, McKenna W,et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet. 2008;82:809–21. - PMC - PubMed
-
- Milting H, Klauke B, Christensen AH, Müsebeck J, Walhorn V, Grannemann S, Münnich T, Šarić T, Rasmussen TB, Jensen HK, et al. The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. Eur Heart J. 2015;36:872–81. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
